Latanoprost for uncontrolled glaucoma in a compassionate case protocol

B. Patelska, David Greenfield, J. M. Liebmann, M. Wand, H. Kushnick, R. Ritch

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

PURPOSE: To evaluate the ocular hypotensive response of latanoprost 0.005% administered as adjunctive therapy in patients with glaucoma who were receiving maximal tolerated medical therapy. METHODS: Consecutive patients entering a latanoprost compassionate clinical trial were enrolled at two sites. Latanoprost 0.005% was administered as a single drop between 6 and 8 PM, and all other medications were continued. Intraocular pressure was measured between 2 and 4 PM. Responders were defined as having a reduction in intraocular pressure of at least 20% from baseline. RESULTS: In 160 eyes of 160 patients, mean baseline intraocular pressure ± SD was 23.3 ± 6.9 mm Hg. Intraocular pressure was significantly reduced compared with baseline measurements (P < .01) with mean intraocular pressure measurements reductions of 4.1 ± 5.2, 4.0 ± 6.3, and 3.7 ± 4.2 mm Hg at the 1-, 3-, and 6-month intervals, respectively. A reduction in intraocular pressure of at least 20% was observed in 64 (44.4%) of 144 patients, 46 (43.0%) of 107 patients, and 10 (32.3%) of 31 patients of the 1-, 3-, and 6-month visits, respectively. A 40% reduction in intraocular pressure was observed in 18 (12.5%) of 144 and nine (8.4%) of 107 patients at 1 and 3 months, respectively. Mean reduction in intraocular pressure was similar in the miotic and nonmiotic groups (P > .4 at all intervals). Eight patients (5.0%) developed ocular allergy or irritation necessitating cessation of latanoprost therapy. CONCLUSION: Latanoprost 0.005% may provide significant further intraocular pressure reduction in patients already receiving maximal tolerated medical therapy.

Original languageEnglish
Pages (from-to)279-286
Number of pages8
JournalAmerican Journal of Ophthalmology
Volume124
Issue number3
StatePublished - Sep 25 1997
Externally publishedYes

Fingerprint

latanoprost
Intraocular Pressure
Glaucoma
Therapeutics
Hypersensitivity
Clinical Trials

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Patelska, B., Greenfield, D., Liebmann, J. M., Wand, M., Kushnick, H., & Ritch, R. (1997). Latanoprost for uncontrolled glaucoma in a compassionate case protocol. American Journal of Ophthalmology, 124(3), 279-286.

Latanoprost for uncontrolled glaucoma in a compassionate case protocol. / Patelska, B.; Greenfield, David; Liebmann, J. M.; Wand, M.; Kushnick, H.; Ritch, R.

In: American Journal of Ophthalmology, Vol. 124, No. 3, 25.09.1997, p. 279-286.

Research output: Contribution to journalArticle

Patelska, B, Greenfield, D, Liebmann, JM, Wand, M, Kushnick, H & Ritch, R 1997, 'Latanoprost for uncontrolled glaucoma in a compassionate case protocol', American Journal of Ophthalmology, vol. 124, no. 3, pp. 279-286.
Patelska B, Greenfield D, Liebmann JM, Wand M, Kushnick H, Ritch R. Latanoprost for uncontrolled glaucoma in a compassionate case protocol. American Journal of Ophthalmology. 1997 Sep 25;124(3):279-286.
Patelska, B. ; Greenfield, David ; Liebmann, J. M. ; Wand, M. ; Kushnick, H. ; Ritch, R. / Latanoprost for uncontrolled glaucoma in a compassionate case protocol. In: American Journal of Ophthalmology. 1997 ; Vol. 124, No. 3. pp. 279-286.
@article{1d20794206624167b3ee561b3cba368b,
title = "Latanoprost for uncontrolled glaucoma in a compassionate case protocol",
abstract = "PURPOSE: To evaluate the ocular hypotensive response of latanoprost 0.005{\%} administered as adjunctive therapy in patients with glaucoma who were receiving maximal tolerated medical therapy. METHODS: Consecutive patients entering a latanoprost compassionate clinical trial were enrolled at two sites. Latanoprost 0.005{\%} was administered as a single drop between 6 and 8 PM, and all other medications were continued. Intraocular pressure was measured between 2 and 4 PM. Responders were defined as having a reduction in intraocular pressure of at least 20{\%} from baseline. RESULTS: In 160 eyes of 160 patients, mean baseline intraocular pressure ± SD was 23.3 ± 6.9 mm Hg. Intraocular pressure was significantly reduced compared with baseline measurements (P < .01) with mean intraocular pressure measurements reductions of 4.1 ± 5.2, 4.0 ± 6.3, and 3.7 ± 4.2 mm Hg at the 1-, 3-, and 6-month intervals, respectively. A reduction in intraocular pressure of at least 20{\%} was observed in 64 (44.4{\%}) of 144 patients, 46 (43.0{\%}) of 107 patients, and 10 (32.3{\%}) of 31 patients of the 1-, 3-, and 6-month visits, respectively. A 40{\%} reduction in intraocular pressure was observed in 18 (12.5{\%}) of 144 and nine (8.4{\%}) of 107 patients at 1 and 3 months, respectively. Mean reduction in intraocular pressure was similar in the miotic and nonmiotic groups (P > .4 at all intervals). Eight patients (5.0{\%}) developed ocular allergy or irritation necessitating cessation of latanoprost therapy. CONCLUSION: Latanoprost 0.005{\%} may provide significant further intraocular pressure reduction in patients already receiving maximal tolerated medical therapy.",
author = "B. Patelska and David Greenfield and Liebmann, {J. M.} and M. Wand and H. Kushnick and R. Ritch",
year = "1997",
month = "9",
day = "25",
language = "English",
volume = "124",
pages = "279--286",
journal = "American Journal of Ophthalmology",
issn = "0002-9394",
publisher = "Elsevier USA",
number = "3",

}

TY - JOUR

T1 - Latanoprost for uncontrolled glaucoma in a compassionate case protocol

AU - Patelska, B.

AU - Greenfield, David

AU - Liebmann, J. M.

AU - Wand, M.

AU - Kushnick, H.

AU - Ritch, R.

PY - 1997/9/25

Y1 - 1997/9/25

N2 - PURPOSE: To evaluate the ocular hypotensive response of latanoprost 0.005% administered as adjunctive therapy in patients with glaucoma who were receiving maximal tolerated medical therapy. METHODS: Consecutive patients entering a latanoprost compassionate clinical trial were enrolled at two sites. Latanoprost 0.005% was administered as a single drop between 6 and 8 PM, and all other medications were continued. Intraocular pressure was measured between 2 and 4 PM. Responders were defined as having a reduction in intraocular pressure of at least 20% from baseline. RESULTS: In 160 eyes of 160 patients, mean baseline intraocular pressure ± SD was 23.3 ± 6.9 mm Hg. Intraocular pressure was significantly reduced compared with baseline measurements (P < .01) with mean intraocular pressure measurements reductions of 4.1 ± 5.2, 4.0 ± 6.3, and 3.7 ± 4.2 mm Hg at the 1-, 3-, and 6-month intervals, respectively. A reduction in intraocular pressure of at least 20% was observed in 64 (44.4%) of 144 patients, 46 (43.0%) of 107 patients, and 10 (32.3%) of 31 patients of the 1-, 3-, and 6-month visits, respectively. A 40% reduction in intraocular pressure was observed in 18 (12.5%) of 144 and nine (8.4%) of 107 patients at 1 and 3 months, respectively. Mean reduction in intraocular pressure was similar in the miotic and nonmiotic groups (P > .4 at all intervals). Eight patients (5.0%) developed ocular allergy or irritation necessitating cessation of latanoprost therapy. CONCLUSION: Latanoprost 0.005% may provide significant further intraocular pressure reduction in patients already receiving maximal tolerated medical therapy.

AB - PURPOSE: To evaluate the ocular hypotensive response of latanoprost 0.005% administered as adjunctive therapy in patients with glaucoma who were receiving maximal tolerated medical therapy. METHODS: Consecutive patients entering a latanoprost compassionate clinical trial were enrolled at two sites. Latanoprost 0.005% was administered as a single drop between 6 and 8 PM, and all other medications were continued. Intraocular pressure was measured between 2 and 4 PM. Responders were defined as having a reduction in intraocular pressure of at least 20% from baseline. RESULTS: In 160 eyes of 160 patients, mean baseline intraocular pressure ± SD was 23.3 ± 6.9 mm Hg. Intraocular pressure was significantly reduced compared with baseline measurements (P < .01) with mean intraocular pressure measurements reductions of 4.1 ± 5.2, 4.0 ± 6.3, and 3.7 ± 4.2 mm Hg at the 1-, 3-, and 6-month intervals, respectively. A reduction in intraocular pressure of at least 20% was observed in 64 (44.4%) of 144 patients, 46 (43.0%) of 107 patients, and 10 (32.3%) of 31 patients of the 1-, 3-, and 6-month visits, respectively. A 40% reduction in intraocular pressure was observed in 18 (12.5%) of 144 and nine (8.4%) of 107 patients at 1 and 3 months, respectively. Mean reduction in intraocular pressure was similar in the miotic and nonmiotic groups (P > .4 at all intervals). Eight patients (5.0%) developed ocular allergy or irritation necessitating cessation of latanoprost therapy. CONCLUSION: Latanoprost 0.005% may provide significant further intraocular pressure reduction in patients already receiving maximal tolerated medical therapy.

UR - http://www.scopus.com/inward/record.url?scp=0030885160&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030885160&partnerID=8YFLogxK

M3 - Article

C2 - 9439353

AN - SCOPUS:0030885160

VL - 124

SP - 279

EP - 286

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

SN - 0002-9394

IS - 3

ER -